News & Events

Michael Bader has received over half a million euros from the LEO Foundation. The funding will help him develop a therapy for vitiligo and other inflammatory skin conditions. He hopes the answer lies in an ointment that inhibits ACE2, an enzyme that gained global attention during the coronavirus pandemic.

This woman knows what a good book is. Petra Nibbe used to be a bookseller before she moved into the world of business law and human resources management. Nibbe, who is now head of the People and Culture Department at the Max Delbrück Center, takes us to Georgia, to the era after the collapse of the Soviet Union.

For Ukrainian graduate students, it can be a struggle to balance their careers and their worries about the war and their loved ones. A profile of two Ukrainian friends who work at the Max Delbrück Center now – one year after they had to flee from Kyiv.

Chromatin factors are involved in regulating gene expression. If they do not function properly, this can result in neurological impairments. Ana Pombo and Alexander Kukalev are now receiving almost €400,000 from the DFG for a research project that aims to shed more light on how these factors work.

Hypertension can damage the heart, brain, and blood vessels. The immune system plays an important role in this process, Suphansa Sawamiphak from the Max Delbrück Center reports in Cardiovascular Research. The study, using zebrafish, found that inflammation causes macrophages to damage blood vessels instead of protecting them.

HeLa contributed to more than 75,000 studies, some of them at the Max Delbrück Center. The cell culture line is indispensable to many biomedical laboratories. But who was the woman behind this abbreviation? During Black History Month we are celebrating her legacy—and our researchers say “Thank you!”

Dominik Müller investigates how lifestyle affects the molecular regulation processes in the body – such as how a high-sodium diet impacts the immune system and cardiovascular health. In doing so, he deliberately transcends the boundaries between disciplines.

MyoPax develops regenerative therapies for previously incurable muscle diseases. An interview with co-founders Prof. Simone Spuler and Dr. Verena Schöwel-Wolf, now board member and CEO respectively